These findings indicate that pharmacologically-mediated reduction of CD38 levels in the tumor microenvironment alone did not elicit anti-tumorigenic responses in syngeneic lung cancers that are basally resistant to checkpoint blockade. This evidence concerns the gene CD38 and lung carcinoma.